Huan Qiu Wang·2026-02-27 07:33Core Viewpoint - BeiGene reported a total revenue of 38.205 billion yuan for the fiscal year 2025, representing a year-on-year growth of 40.4% driven by product revenue growth and improved operational efficiency through cost management [1] Group 1: Financial Performance - The net profit attributable to the parent company reached 1.422 billion yuan during the reporting period [1] - Product revenue amounted to 37.77 billion yuan, showing a year-on-year increase of 39.9% [1] Group 2: Product Sales - The global sales of the product Brukinsa® (Zebutinib) reached 28.067 billion yuan, with a year-on-year growth of 48.8% [1] - In the U.S. market, Brukinsa® sales were 20.206 billion yuan, reflecting a year-on-year increase of 45.5% [1] - In Europe, Brukinsa® sales reached 4.265 billion yuan, growing by 66.4% year-on-year [1] - In China, Brukinsa® sales were 2.472 billion yuan, with a year-on-year growth of 33.1% [1] - Another core product, Tislelizumab (百泽安®), achieved global sales of 5.297 billion yuan, marking an 18.6% increase year-on-year [1] Group 3: Future Prospects - BeiGene plans to submit a new indication application for Tislelizumab combined with Zanidatamab (Zanidatamab) for first-line treatment of HER2-positive gastric adenocarcinoma in adults in the U.S. and China in the first half of 2026 [1] - The company anticipates a regulatory decision in Japan for the same indication in the second half of 2026 [1]